Royalty Pharma Sub-Manager, LLC originally filed its 13F report for Q2 2026 on August 14, 2026. The filing was subsequently amended, with the latest update submitted on August 21, 2026. The portfolio totaled 241.92 M reflecting a +40.03% change from the prior quarter, spanning 4 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 1 new positions and 1 complete exits.
Items:
Total Value:
| Issuer Name | Class | Value | Shares | Option Type |
|---|
Yes. Royalty Pharma Sub-Manager originally filed on 08/14/2026 and subsequently submitted 1 amendment(s). The latest filing (13F-HR/A) was submitted on 08/21/2026.
In the Q2 2026 filing, Royalty Pharma Sub-Manager reported a managed portfolio value of 241.92 M, consisting of 4 individual positions.
Multiple filings indicate that Royalty Pharma Sub-Manager updated their Q2 2026 report. The initial filing was submitted on 08/14/2026, followed by amendments to correct data or disclose previously confidential holdings.
This page displays the raw filing documents. To see which stocks Royalty Pharma Sub-Manager bought or sold during Q2 2026, please visit Royalty Pharma Sub-Manager's Portfolio Analysis page.